ALFRED HEALTH | MedPath

New Teletrial Model Brings Hope to Severe Eczema Patients in Regional Areas

3 days ago

• A groundbreaking clinical trial at Alfred Health is offering new treatment options for severe eczema sufferers through an innovative teletrial model, allowing patients to receive care closer to home. • The international study, also running in the US and Canada, is testing a novel treatment for moderate to severe eczema with Latrobe Regional Health becoming one of the first non-metropolitan hospitals worldwide to participate. • After a year of treatment, the trial's first teletrial participant experienced significant improvement with reduced flare-ups and decreased reliance on steroid medications, demonstrating the potential impact of this accessible care model.

Aravax Appoints Aled Williams as CBO to Spearhead International Expansion of Peanut Allergy Therapy PVX108

4 months ago

• Aravax appointed Aled Williams as Chief Business Officer to bolster its international presence and strategic partnerships. • Williams will focus on expanding the Aravax portfolio and advancing the asset strategy, leveraging his 25 years of biotech and pharma experience. • The appointment supports the Phase 2 development of PVX108, Aravax's lead immunotherapy for peanut allergy, designed for safer and more targeted treatment. • Aravax aims to establish itself as a leader in food allergy treatments through innovative immunotherapies and strategic global outreach.

BTK Degraders Show Promise in Pretreated B-Cell Malignancies

4 months ago

• Novel BTK degraders like AC676, NX-5948, and BGB-16673 are under evaluation in phase 1 trials for relapsed/refractory B-cell malignancies, addressing resistance to BTK inhibitors. • BGB-16673 demonstrated encouraging response rates in follicular lymphoma (50%) and marginal zone lymphoma (67%), with manageable safety profiles in heavily pretreated patients. • NX-5948 showed a 75.5% objective response rate in relapsed/refractory CLL/SLL, with a tolerable safety profile and ongoing studies planned for pivotal trials in 2025. • AC676, a novel BTK chimeric degrader, is in phase 1 dose escalation, showing potential for treating B-cell malignancies, including those with central nervous system involvement.

Aravax Completes Phase 2 Recruitment for PVX108 Peanut Allergy Immunotherapy

7 months ago

• Aravax has finished recruiting 95 participants for its Phase 2 trial (AVX-201) of PVX108, a novel immunotherapy for peanut allergy. • PVX108 is designed to retrain the immune system by targeting T cells with engineered peptides, differing from treatments that use peanut proteins. • The double-blind, placebo-controlled study is evaluating the safety and efficacy of two dose levels of PVX108 in children and adolescents. • Topline results from the Phase 2 study, conducted across U.S. and Australian sites, are anticipated in the first half of 2026.

Aravax Completes Phase 2 Recruitment for PVX108 Peanut Allergy Immunotherapy

7 months ago

• Aravax has finished recruiting 95 participants for its Phase 2 trial (AVX-201) of PVX108, a novel immunotherapy for peanut allergy. • The double-blind, placebo-controlled study assesses the safety and efficacy of two PVX108 doses in children and adolescents aged 4-17. • PVX108 is designed to retrain the immune system without using peanut proteins, potentially avoiding serious side effects associated with other treatments. • Topline results from the Phase 2 study, conducted across U.S. and Australian sites, are anticipated in the first half of 2026.